Human Insulin

Clinical Pharmacological Studies in Normal Man

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Endocrinology & Metabolism
Cover of the book Human Insulin by D.R. Owens, Springer Netherlands
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: D.R. Owens ISBN: 9789400941618
Publisher: Springer Netherlands Publication: December 6, 2012
Imprint: Springer Language: English
Author: D.R. Owens
ISBN: 9789400941618
Publisher: Springer Netherlands
Publication: December 6, 2012
Imprint: Springer
Language: English

Since insulin became available for the treatment of diabetes in 1922 a number of major advances have been made, which include the modification of insulin to vary its timing of action, its purification, and latterly, the production of human insulin. Human insulin in quantities sufficiently large for therapy has been made available by two techniques developed in parallel during the late 1970s. These involve either (i) formulation in E. coli bacteria suitably encoded by DNA recombinant methods of the A- and B-chains of human insulin followed by a chain combination reaction ('biosynthetic' human insulin) or (ii) enzymatic conversion (transpeptidation) of porcine insulin brought to react with a threonine ester by porcine trypsin in a mixture of water and organic solvents, yielding human insulin ('semi-synthetic' human insulin). This book includes the first clinical-pharmacological studies of each of the highly purified 'semi-synthetic' human insulin preparations: Actrapid ® HM; Monotard® HM; Protaphane® HM; Actraphane® HM; and Ultratard® HM (Novo Industri A/S, Copenhagen). The preliminary studies established their safety and efficacy relative to their porcine and bovine counterparts emphasising the relevance of species and formulation on the pharmacokinetics and biological responses to insulin. Additional investigations with human insulin demonstrated the influence of insulin concentration, site of administration, the addition of aprotinin to insulin and the mixing of 'short-' and 'intermediate-acting' formulations on insulin 'bioavailability'. Examination of the 'within' and 'between' subject day-to-day variation in absorption and the effect of subcutaneous insulin also demonstrates the dominating influence of insulin responsiveness.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Since insulin became available for the treatment of diabetes in 1922 a number of major advances have been made, which include the modification of insulin to vary its timing of action, its purification, and latterly, the production of human insulin. Human insulin in quantities sufficiently large for therapy has been made available by two techniques developed in parallel during the late 1970s. These involve either (i) formulation in E. coli bacteria suitably encoded by DNA recombinant methods of the A- and B-chains of human insulin followed by a chain combination reaction ('biosynthetic' human insulin) or (ii) enzymatic conversion (transpeptidation) of porcine insulin brought to react with a threonine ester by porcine trypsin in a mixture of water and organic solvents, yielding human insulin ('semi-synthetic' human insulin). This book includes the first clinical-pharmacological studies of each of the highly purified 'semi-synthetic' human insulin preparations: Actrapid ® HM; Monotard® HM; Protaphane® HM; Actraphane® HM; and Ultratard® HM (Novo Industri A/S, Copenhagen). The preliminary studies established their safety and efficacy relative to their porcine and bovine counterparts emphasising the relevance of species and formulation on the pharmacokinetics and biological responses to insulin. Additional investigations with human insulin demonstrated the influence of insulin concentration, site of administration, the addition of aprotinin to insulin and the mixing of 'short-' and 'intermediate-acting' formulations on insulin 'bioavailability'. Examination of the 'within' and 'between' subject day-to-day variation in absorption and the effect of subcutaneous insulin also demonstrates the dominating influence of insulin responsiveness.

More books from Springer Netherlands

Cover of the book Landscape Development and Climate Change in Southwest Bulgaria (Pirin Mountains) by D.R. Owens
Cover of the book Environmental Communication. Second Edition by D.R. Owens
Cover of the book Introduction to Modern Sleep Technology by D.R. Owens
Cover of the book Ultrasound Technology in Green Chemistry by D.R. Owens
Cover of the book Drugs and the Liver: High Risk Patients and Transplantation by D.R. Owens
Cover of the book Regional Fisheries Oceanography of the California Current System by D.R. Owens
Cover of the book Dynamic Semantics by D.R. Owens
Cover of the book Subduction by D.R. Owens
Cover of the book Data in Medicine: Collection, Processing and Presentation by D.R. Owens
Cover of the book Edible Medicinal And Non-Medicinal Plants by D.R. Owens
Cover of the book Higher Education in Portugal 1974-2009 by D.R. Owens
Cover of the book The Law on Medicines by D.R. Owens
Cover of the book Classification, Disease and Evidence by D.R. Owens
Cover of the book Problems in Historical Epistemology by D.R. Owens
Cover of the book Analytical Transmission Electron Microscopy by D.R. Owens
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy